Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 117

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 117
---
 Business    
 Combination; (ix) 6,127 shares of Common Stock issuable upon the exercise of warrants to purchase shares of our Common Stock sold to         
 certain investors pursuant to the First Securities Purchase Agreement; (x) 50,000 shares of Common Stock issuable upon the exercise of       
 warrants to purchase shares of our Series A Preferred Stock sold to certain investors pursuant to the First and Second Securities Purchase   
 Agreement and conversion of the underlying shares of Series A Preferred Stock into Common Stock and (xi) 4,425 shares of Common Stock        
 issuable upon the exercise of Private Placement Warrants to purchase shares of our Common Stock, at an exercise price of $1,150.00 per       
 share, that were originally sold in a private placement concurrently with the Initial Public Offering; and (2) the issuance by us of         
 up to 87,500 shares of Common Stock issuable upon the exercise of public warrants to purchase shares of our Common Stock, at an exercise     
 price of $1,150.00 per share, that were originally issued in the Initial Public Offering;                                                    |

| ● | a registration statement with                                                                                                            
 the SEC for purposes of registering of the resale from time to time of up to 6,385,638 shares of Common Stock, which consists of (i)     
 576,710 shares of Common Stock issuable upon the conversion of shares of our Series A Preferred Stock purchased by certain investors     
 pursuant to the First Securities Purchase Agreement; (ii) 91,829 shares of Common Stock issuable upon the conversion of shares of our    
 Series B Preferred Stock purchased by certain investors pursuant to the Second Securities Purchase Agreement; (iii) 707,394 shares of    
 Common Stock issued upon the conversion of shares of our Series A Preferred Stock and Series B Preferred Stock; (iv) 4,366,837 shares    
 of Common Stock issuable upon the conversion of 300% of the number of outstanding shares of our Series C Preferred Stock purchased by    
 certain investors pursuant to the Third Securities Purchase Agreement; (v) 2,500 shares of Common Stock issued to a stockholder in a     
 reallocation of shares in connection with the consummation of the Business Combination; (vi) 81,752 shares of Common Stock issuable upon 
 the exercise of warrants to purchase shares of our Common Stock, at an exercise price of $9.80 per share, which warrants were sold to    
 certain investors pursuant to the Third Securities Purchase Agreement (the “Series C Warrants”);